| Literature DB >> 33632452 |
Elif Gokcal1, Mitchell J Horn1, M Edip Gurol2.
Abstract
Stroke prevention in patients with atrial fibrillation is arguably one of the fastest developing areas in preventive medicine. The increasing use of direct oral anticoagulants and nonpharmacologic methods such as left atrial appendage closure for stroke prevention in these patients has increased clinicians' options for optimal care. Platelet antiaggregants are also commonly used in other ischemic cardiovascular and or cerebrovascular conditions. Long term use of oral anticoagulants for atrial fibrillation is associated with elevated risks of major bleeds including especially brain hemorrhages, which are known to have extremely poor outcomes. Neuroimaging and other biomarkers have been validated to stratify brain hemorrhage risk among older adults. A thorough understanding of these biomarkers is essential for selection of appropriate anticoagulant or left atrial appendage closure for stroke prevention in patients with atrial fibrillation. This article will address advances in the stratification of ischemic and hemorrhagic stroke risk among patients with atrial fibrillation and other conditions.Entities:
Keywords: Anticoagulation; Antithrombotic; Cerebral amyloid angiopathy; Hypertensive cerebral hemorrhage; Intracerebral hemorrhage; Platelet antiaggregants; Risk scores; Stroke prevention
Mesh：
Substances：
Year: 2021 PMID： 33632452 PMCID： PMC9044196 DOI： 10.1016/B978-0-12-819814-8.00021-4
Source DB: PubMed Journal: Handb Clin Neurol ISSN： 0072-9752